Signal
Eli Lilly Q3 2026: Revenue Up 39% YoY, FY Guidance Raised to $91-92B
Key Facts
Signal Type
Signal
Industry
Biotech
Companies
Eli Lilly (LLY)
Date
October 29, 2026
Eli Lilly delivered its strongest quarter of 2026, with revenue growing 39% year-over-year and the combined Mounjaro and Zepbound franchise crossing $16B in a single quarter. Gross margin expansion and operating leverage pushed non-GAAP performance margin above 54%, supporting another upward revision to full-year guidance.
U.S. revenue grew 34%, primarily on Zepbound and Mounjaro volume, partially offset by a 7% price decline. Excluding a favorable rebate adjustment, U.S. price declined 10%, confirming that realized pricing remains a structural headwind even as volume accelerates.
International growth was even faster. Europe revenue grew 29% in constant currency, Japan 26%, China 62%, and rest of world 87%. Mounjaro became the first medicine in China to exceed $1B revenue in its first full year, a notable milestone for market penetration in a historically difficult region.
CEO Dave Ricks described Q3 as another quarter of solid execution, pointing to raised guidance, pipeline advancement, and manufacturing expansion as the three pillars of the period. He emphasized that oncology, immunology, and neuroscience portfolio revenue doubled versus last year, reducing dependence on incretins alone.
The Medicare GLP-1 Bridge Program, launched July 1, has already seen more than half a million prescriptions filled. Among new bridge patients, seven out of ten are starting on a Lilly obesity medicine, giving the company an early share lead in this expanded access channel.
Ricks cited a USC Schaeffer Center estimate that Medicare anti-obesity medication expansion could deliver over $20B in cumulative savings over ten years. This data point matters because it gives policymakers a fiscal argument for broader coverage, which would directly benefit Lilly's obesity franchise.
CFO Lucas Montarce noted that 2026 benefited from approximately $2B in one-time items, including milestone payments and rebate estimate changes, that will not recur in 2027. He flagged net realized price as an expected 2027 headwind, partially offset by volume growth from the Bridge Program and Foundayo launches.
On the pipeline front, Chief Scientific Officer Dan Skovronsky highlighted retatrutide's TRANSCEND-T2D-2 results, where the triple agonist delivered 20-21% weight loss versus 9.4% for semaglutide. He also presented EloraTZP phase II data showing 23.3% weight loss at 48 weeks, 57% more than tirzepatide alone.
Skovronsky acknowledged that the highest EloraTZP dose arm had elevated discontinuation rates due to adverse events. Phase III trials will use a slower dose escalation schedule to improve tolerability, an important design choice for preserving the efficacy-tolerability balance.
The incretin market is expanding faster than most analysts modeled at the start of 2026. U.S. obesity incretin prescriptions grew 82% year-over-year, and total U.S. incretin prescriptions grew 32%. The Medicare Bridge Program is a structural demand catalyst, adding roughly 20 million seniors to the addressable obesity market.
Lilly's international share reached approximately 58%, up nearly four percentage points from Q2 2026. This share gain matters because international markets are earlier in their obesity treatment adoption curve, meaning Lilly is establishing brand preference before competitors scale distribution.
The Foundayo oral launch is gaining traction, with four in ten patients starting an oral obesity medicine choosing it. New Foundayo patients doubled from Q2 to Q3, and a U.S. type 2 diabetes approval could arrive in Q4, broadening the label beyond obesity.
Outside cardiometabolic health, the diversified portfolio is gaining scale. Kisunla revenue grew 175% year-over-year in neuroscience, Ebglyss grew 59% in immunology, and Jaypirca grew 59% in oncology. While these are smaller in absolute dollars, they reduce concentration risk and validate Lilly's R&D engine across therapeutic areas.
The two manufacturing facility groundbreakings, $6.5B in Houston and $5B in Richmond, signal that Lilly is investing ahead of demand. Supply has been the binding constraint for incretins industry-wide, and these facilities should support volume growth into the late 2020s.
The AtaiBeckley and Merida acquisitions add neuroplastogen and precision immunology assets, respectively. Neither is near-term revenue, but both fit Lilly's pattern of acquiring differentiated early-stage programs rather than late-stage commercial assets.
Leadership transition is underway, with Patrik Jonsson retiring at year-end and Ilya Yuffa expanding to President of Lilly Global Markets. This consolidates U.S. and international commercial leadership under one executive, which should improve global launch coordination.
I would watch four things over the next two quarters:
Source:
FortuneGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
